Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05824689 · OUTCOME

Occurrence/Risk of Febrile Neutropenia (FN)

Fluoroquinolone Resistance Prevalence Study · Source last updated 2026-06-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Within 28 days of the transplantation

What was measured

Occurrence of neutropenic fever during the first 28 days (4 weeks) after autologous PBSC transplantation in the treatment of multiple myeloma.

Analysis population: Analysis separated by FRE Positive and Negative Participants

Groups in this outcome

Enrolled Participants

Subjects eligible for this study will meet the defined eligibility criteria to undergo autologous transplantation established at the transplant centers as per standard of care (SOC). All adult patients with a diagnosis of multiple myeloma undergoing autologous transplantation after dose-intense melphalan conditioning are candidates for enrollment into this study. These subjects will be approached for enrollment into this study by the transplant attending physician caring for the patient

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Enrolled Participants117

Reported measurements

FRE Neg Participants

Analysis denominator · Participants

GroupSource count
Enrolled Participants94
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enrolled Participants22Not reportedNot reportedNot reportedNot reported
FRE Positive Participants

Analysis denominator · Participants

GroupSource count
Enrolled Participants23
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enrolled Participants6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        22
    denoms
    1. counts
      1. group Id
        OG000
        value
        94
      units
      Participants
    title
    FRE Neg Participants
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    denoms
    1. counts
      1. group Id
        OG000
        value
        23
      units
      Participants
    title
    FRE Positive Participants
denoms
  1. counts
    1. group Id
      OG000
      value
      117
    units
    Participants
description
Occurrence of neutropenic fever during the first 28 days (4 weeks) after autologous PBSC transplantation in the treatment of multiple myeloma.
groups
  1. description
    Subjects eligible for this study will meet the defined eligibility criteria to undergo autologous transplantation established at the transplant centers as per standard of care (SOC). All adult patients with a diagnosis of multiple myeloma undergoing autologous transplantation after dose-intense melphalan conditioning are candidates for enrollment into this study. These subjects will be approached for enrollment into this study by the transplant attending physician caring for the patient
    id
    OG000
    title
    Enrolled Participants
param Type
COUNT_OF_PARTICIPANTS
population Description
Analysis separated by FRE Positive and Negative Participants
reporting Status
POSTED
time Frame
Within 28 days of the transplantation
title
Occurrence/Risk of Febrile Neutropenia (FN)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice